David H. Fine, PhD

Executive Chairman and Chief Scientific Officer

Dr. David H. Fine is the founder and Executive Chairman and Chief Scientific Officer of GeNO. From inception until December 2011, he was President and from inception until August 2013 he was Chief Executive Officer. Dr. Fine has served as a Manager of GeNO since 2006.

Dr. Fine has 40 years of experience leading innovation development and transitioning high technology chemistry-based instruments from research through production and into commercialization. In 2000, Dr. Fine co-founded CyTerra Corporation, a company focused on advanced technology for the detection of buried land mines. Dr. Fine served as Chief Executive Officer of CyTerra from 2000 until 2006. Prior to co-founding CyTerra, Dr. Fine worked for 28 years at Thermo Electron Corporation. During his tenure at Thermo Electron, Dr. Fine published extensively on the formation of carcinogenic N-nitrosamines, the detection of NO and NO2 using chemiluminescence, the detection of explosives for forensic and airport security by converting them to NO, and then measuring the NO, and many other detection systems using the NO moiety. Dr. Fine held various leadership positions at Thermo Electron, including Vice President of Thermedics Inc. and Senior Vice President of Thermedics Detection Inc., both of which were publicly-traded subsidiaries of Thermo Electron. His last assignment at Thermo Electron was as President of Thermo Electron’s R&D Center Inc. From 1969 to 1972, while on the academic staff of the Chemical Engineering Department at MIT, Dr. Fine worked on the formation and mitigation of NO formed in combustion systems and NO related air pollution chemistry. Dr. Fine has published over 100 technical papers in refereed technical literature, including Nature and Science. He is also the inventor on 71 issued U.S. patents including over 50 patents on NO/NO2 based chemistry and instrumentation.

Kurt Dasse, PhD

President and Chief Executive Officer

Dr. Kurt A. Dasse is the President and Chief Executive Officer of GeNO. He became Executive Vice President in December 2011, President in December 2012 and Chief Executive Officer in August 2013. From 2007 to 2011, Dr. Dasse served as a non-employee member of our Board of Managers and has remained a Manager since joining the Company in an executive capacity in 2011.

Dr. Dasse has spent nearly three decades conducting research in cardiovascular disorders and developing products to treat heart and renal failure. He has extensive experience in designing, developing and commercializing products and in obtaining the required regulatory approvals. From 2006 to 2011, he served as President and CEO of Levitronix LLC, a developer and manufacturer of a new generation of blood pumps for the medical industry, including the CentriMag, PediMag and PediVAS devices, and ultra-pure fluid handling components for the semiconductor industry. The medical business of Levitronix was sold to Thoratec Corp. in August 2011. From 2000 to 2006, Dr. Dasse served as President of the Medical Division of Levitronix, LLC. From 1997 to 2000, Dr. Dasse was Chief Scientist and Vice-President of Thermo Electron Corporation’s Biomedical Group, where he focused on developing products for the respiratory, neurodiagnostic, cardiovascular and imaging markets. He also was one of the founding officers of Thermo Cardiosystems and played a key role in the development and commercialization of the original HeartMate LVAD, the first implantable ventricular assist system for end-stage heart-failure patients. Dr. Dasse has written more than 100 journal articles and multiple book chapters and holds multiple patents. Dr. Dasse has extensive experience in winning 510(k)’s, IDE’s, PMA’s, CE Marks and international approvals for devices such as blood pumps, ventricular assist systems, drive consoles, peritoneal dialysis catheters, digital mammography equipment and software.


Robert F. Roscigno, PhD

Executive Vice-President , Global Clinical Affairs

Dr. Robert Roscigno is the Executive Vice President, Global Clinical Affairs of GeNO, and has served as a consultant and/or employee of GeNO since 2008. Dr. Roscigno has over 17 years of drug development experience relating to pulmonary hypertension. From 2005 to 2007, Dr. Roscigno was President and COO of Lung Rx, Inc., an affiliate company of United Therapeutics, where he was responsible for the product pipeline and for bringing the company’s lead product Tyvaso successfully through Phase 3 development. From 2000 to 2005, Dr. Roscigno served as Associate Director, Director, Vice President and Senior Vice-President of United Therapeutics Corporation where he helped transform the company from a start-up to a multi-billion dollar company. Dr. Roscigno was also a key contributor in the successful development and worldwide commercialization of Remodulin for the treatment of PAH. He is the co-inventor on five U.S. patents and published numerous articles in scientific journals. Dr.Roscigno has extensive experience in preparing INDs and NDAs for FDA that address PAH indications.

Anthony Loumidis

Chief Financial Officer and Treasurer

Mr. Loumidis was appointed as the Chief Financial Officer and Treasurer of GeNO in October 2013. He served as the Chief Financial Officer of American DG Energy Inc. from 2004 and Treasurer from 2001 until October, 2013.  He also served as Chief Financial Officer, Treasurer and Secretary of Eurosite Power Inc. from 2010 to October 2013, and as Vice President and Treasurer of Tecogen Inc., an affiliate of American DG Energy Inc., from 2001 to October 2013.  Prior to 2001, Mr. Loumidis held various positions at Thermo Electron, including National Sales Manager for Thermo Capital Financial Services, Manager of Investor Relations and Manager of Business Development of Tecomet, a subsidiary of Thermo Electron.

Farzad Parsaie

Chief Operating Officer

Mr. Parsaie was appointed as the Chief Operating Officer of GeNO in October 2013. Mr. Parsaie has over 20 years of experience in the medical device industry and has extensive experience managing projects and operations and commercializing products in FDA regulated environments. Since 2011, Mr. Parsaie has consulted for medical device, pharmaceutical and nutrition firms in the quality assurance, regulatory affairs, and product strategy domains. From 2007 to 2011, Mr. Parsaie served as the Chief Operating Officer-U.S. for Levitronix LLC, a developer and manufacturer of a new generation of blood pumps for the medical industry, and ultra-pure fluid handling components for the semiconductor industry. Prior to 2007, Mr. Parsaie held management positions in quality assurance, regulatory affairs, research and development, program management and marketing at Boston Scientific, Thermo Cardiosystems, Medtronic and CR Bard.